Loading...
Please wait, while we are loading the content...
Similar Documents
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
| Content Provider | MDPI |
|---|---|
| Author | Tomasz, Szydełko D’Andrea, David D’Altilia, Nicola Giudice, Francesco Del Flammia, Rocco Simone Chung, Benjamin I. Moschini, Marco Pradere, Benjamin Mari, Andrea Soria, Francesco Albisinni, Simone Krajewski, Wojciech Laukhtina, Ekaterina Gallioli, Andrea Mertens, Laura S. Maggi, Martina Sciarra, Alessandro Salciccia, Stefano Ferro, Matteo Scornajenghi, Carlo Maria Asero, Vincenzo Cattarino, Susanna Angelis, Mario De Cacciamani, Giovanni E. Autorino, Riccardo Pandolfo, Savio Domenico Falagario, Ugo Giovanni Mancini, Vito Chirico, Marco Cinelli, Francesco Bettocchi, Carlo Cormio, Luigi Carrieri, Giuseppe Berardinis, Ettore De Busetto, Gian Maria Party, European Association of Urology (E A.U)—Young Academic Urologists (Y A.U) Urothelial Cancer Working |
| Copyright Year | 2022 |
| Description | Background: Intravesical immunotherapy with bacillus Calmette–Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. Methods: Patients with NMIBCs underwent adjuvant induction ± maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naïve patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan–Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed. Results: 852 Ta-T1 NMIBCs (n = 719, 84.4% on TICE; n = 133, 15.6% on RIVM) with a median of 53 (24–77) months of follow-up were reviewed. After PSM, no differences at 5-years RFS, PFS, and CSS at both Kaplan–Meier and Cox regression analyses were detected for the whole cohort. In the sub-group setting of full adherence to European/American Urology Guidelines (EAU/NCCN), BCG TICE demonstrated longer 5-years RFS compared to RIVM (68% vs. 43%, p = 0.008; HR: 0.45 95% CI 0.25–0.81). Conclusion: When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively. |
| Starting Page | 887 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers14040887 |
| Journal | Cancers |
| Issue Number | 4 |
| Volume Number | 14 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-02-10 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Bladder Cancer Re-tur Bcg Strain Bcg-tice Bcg-rivm Recurrence-free Survival Progression-free Survival Cancer-specific Survival |
| Content Type | Text |
| Resource Type | Article |
